Working… Menu

Effect of Rosuvastatin in Abdominal Sepsis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00357123
Recruitment Status : Unknown
Verified September 2010 by Universidad Autonoma de San Luis Potosí.
Recruitment status was:  Recruiting
First Posted : July 27, 2006
Last Update Posted : February 21, 2011
Information provided by:
Universidad Autonoma de San Luis Potosí

Brief Summary:
The purpose of this study is to determine whether rosuvastatin is effective as a coadjuvant drug in the integral management of abdominal sepsis acknowledged by surgery.

Condition or disease Intervention/treatment Phase
Sepsis Drug: Rosuvastatin Phase 2

Detailed Description:

The sepsis is often lethal, the mortality's ranks are identified among 25 to 70%, this depends on definition, severity and co-morbidities. The number of deaths by sepsis could be similar to myocardial infarct. Patients who get shock have 26-fold risk of death.

In preliminary studies have been observed, that patients with treatment with statin have minor incidence of severe sepsis. A retrospective study suggests the association between using statins and reduction of bacteriemia by Gram negatives and S. aureus.

There are many experimental studies which demonstrate the possible profit in sepsis. However there are no clinical prospective studies for determinate if statins are effective in management of sepsis. The investigators designed this study to demonstrate the utility of rosuvastatin in one kind of sepsis, abdominal sepsis.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Use of Rosuvastatin in Integral Management of Abdominal Sepsis
Study Start Date : August 2006
Estimated Primary Completion Date : July 2011
Estimated Study Completion Date : September 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sepsis

Intervention Details:
  • Drug: Rosuvastatin
    20 mg 10 days daily since abdominal sepsis diagnosis
    Other Name: Crestor

Primary Outcome Measures :
  1. Plasmatic levels of Interleukine 6 and 1B, and Tumor Necrosis Factor alpha (pg/dL) [ Time Frame: day 3 ]

Secondary Outcome Measures :
  1. Number of survivors [ Time Frame: 1 week after randomization ]
    in-patient follow-up will be considered as well

  2. Plasmatic levels of Reactive C Protein (mg/dL) [ Time Frame: day 3 ]
  3. Classification of severity by APACHE II scale [ Time Frame: day 3 ]
  4. Incidence of complications or secondary effects [ Time Frame: day 1, 3, 7, 14 after randomization ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Man or women > 18 and < 80 years old with abdominal sepsis, confirmed diagnosis by surgery of broad peritonitis before 48 hours in progression
  2. Injury by steel or firearm with contaminated abdominal cavity
  3. APACHE II major or equal than 8
  4. Acceptance to be included

Exclusion Criteria:

  1. Ingestion of: fibrates, niacin, cyclosporin, azoles, macrolides, inhibitors of protease, nefazodone, verapamil, diltiazem, amiodarone
  2. Hypovolemic shock III and IV after get surgery
  3. Cardio-respiratory failure pre or trans surgery
  4. Allergy to used drug
  5. Use previous of statin
  6. Hepatopathy or myopathy and(or) history, hepatic failure (Child B y C)
  7. Management in other Hospital
  8. Pregnancy
  9. Thoracic injury, head injury (moderate and severe), multiple fractures or with bone exposition, rectal injury

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00357123

Layout table for location contacts
Contact: Martin Sanchez-Aguilar, MSc 524448262345
Contact: Antonio Gordillo-Moscoso, PhD 524448262345 ext 519

Layout table for location information
Hospital Central "Dr. Ignacio Morones Prieto Recruiting
San Luis Potosi, Mexico, 78240
Sub-Investigator: Lorenzo Guevara-Torres, MD         
Sub-Investigator: Jorge H Tapia-Perez, MD         
Sub-Investigator: Martin Sanchez-Aguilar, MSc         
Sponsors and Collaborators
Universidad Autonoma de San Luis Potosí
Layout table for investigator information
Principal Investigator: Martin Sanchez-Aguilar, MSc Experimental Surgery , Universidad Autonoma de San Luis Potosi
Layout table for additonal information
Responsible Party: UASLP, Martin Sanchez Aguilar Identifier: NCT00357123    
Other Study ID Numbers: 28-08 ROAS
First Posted: July 27, 2006    Key Record Dates
Last Update Posted: February 21, 2011
Last Verified: September 2010
Keywords provided by Universidad Autonoma de San Luis Potosí:
abdominal sepsis
Additional relevant MeSH terms:
Layout table for MeSH terms
Systemic Inflammatory Response Syndrome
Pathologic Processes
Rosuvastatin Calcium
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors